Amylyx Pharmaceuticals (AMLX) stock is soaring in pre-market trading on Monday, with shares up 5.61% following a positive analyst action. The biotechnology company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, is seeing increased investor interest after a notable target price revision.

Mizuho, a prominent financial services group, has raised its target price for Amylyx Pharmaceuticals from $16 to $18. This upward revision suggests that the investment firm has a more optimistic outlook on Amylyx's future performance and potential market value. Target price increases often signal confidence in a company's growth prospects or underlying fundamentals, which can lead to increased buying pressure from investors.

The pre-market surge in Amylyx's stock price indicates that investors are reacting positively to Mizuho's more bullish stance. As the market opens, it will be interesting to see if this momentum continues and whether other analysts follow suit with similar upgrades. Investors and market watchers will likely be keeping a close eye on Amylyx Pharmaceuticals throughout the trading day to gauge the full impact of this target price adjustment on the stock's performance.